Ann: Partnership to promote BREVAGenplus, page-3

22 February 2016
Genetic Technologies and IndyCar’s Pippa Mann Announce Partnership to Promote BREVAGenplus®

Melbourne, Australia, 22 February 2016:
Genetic Technologies Limited (ASX: GTG; NASDAQ:
GENE, “Company”), a molecular diagnostics company specialising in women’s health, is pleased to announce a partnership with international race car driver Ms. Pippa Mann to promote BREVAGenplus®, the Company’s first-in-class, clinically validated risk assessment test for sporadic breast cancer.
This agreement marks the Company’s first marketing program, with a national reach, promoting BREVAGenplus in the U.S. and is reflective of Ms.
Mann’s commitment to working with research organisations and corporations who share her passion for reducing the impact that breast cancer has on women.
In addition to Genetic Technologies, Ms. Mann has an established partnership with Susan G. Komen®, the world’s largest breast cancer organisation, which funds more breast cancer research than any other non-profit while providing screening, education, treatment and psychosocial support programs.

“This is an exciting time for the Company as we commence this robust partnership with Pippa.
She represents everything we stand for as a company and shares our passion for the integral role BREVAGenplus can play in women’s health.
She is truly a next generation athlete who is steadfast in leveraging her brand power to promote breast cancer awareness and raise money to help fund cures. Prevention and early detection of breast cancer are central to this mission and the genesis behind her desire to raise the profile of BREVAGenplus as an important breast cancer risk assessment and preventative treatment management tool,” commented Eutillio Buccilli, Executive Director and Chief Executive Officer of Genetic Technologies.

The partnership agreement is inclusive of the BREVAGenplus logo represented on Pippa’s racing car along with racing and promotional apparel.
Ms. Mann will also participate at select BREVAGenplus oriented events and other promotional activities over the course of 2016 (e.g. speaking engagements, social media, print and video campaigns), and related sales support activities.
The 100th running of the Indianapolis 500 on May 29, 2016 will serve as the official launch of the partnership program.
The “Indy 500” is the largest single day sporting event in the world and offers important promotional opportunities during the month long lead-up to the race, which includes 12 days of on-track activities and hospitality event participation.

(The best part )
Ms. Mann is one of only 9 female athletes to ever compete in the “Indy 500” and the only female driver to start in the race over the past 3 consecutive years.
“From my perspective, the partnership is comprehensive in tone, scope and intent.

I am honoured to be working with such a progressive company and, most important, to represent a game-changing product that deserves broader exposure.
The racing community and its fans are diverse in every statistical category and I look forward to working with the Genetic Technologies team to raise the profile of BREVAGenplus among this important audience and beyond,” commented Pippa Mann.